Andrew Hill

Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS

William A. O’Brien, Pamela Hartigan, David E. Martin et al. · New England Journal of Medicine · 1996 · 734 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

François Venter, Michelle Moorhouse, Simiso Sokhela et al. · New England Journal of Medicine · 2019 · 717 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis

Ravindra K. Gupta, Michael R. Jordan, Binta Sultan et al. · The Lancet · 2012 · 368 citations

Public Health, Infectious Disease Control, Pharmacotherapy +11

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

François Venter, Simiso Sokhela, Bryony Simmons et al. · The Lancet HIV · 2020 · 260 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

Jintanat Ananworanich, Angèle Gayet‐Ageron, Michelle Le Braz et al. · The Lancet · 2006 · 240 citations · Full text

Pharmacy, Pharmacotherapy, Hiv Control +9